A COST-EFFECTIVENESS ANALYSIS OF COMMONLY USED BIOLOGIC DRUGS FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE UNITED STATES

被引：0
|
作者：
Wu, J. J. [1 ]
Feldman, S. R. [2 ]
Rastogi, S. [3 ]
Menges, B. [4 ]
Lingohr-Smith, M. [4 ]
Lin, J. [4 ]
机构：
[1] Kaiser Permanente Los Angeles Med Ctr, Los Angeles, CA USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[3] Ortho Dermatol, Bridgewater, NJ USA
[4] Novosys Hlth, Green Brook, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1630
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS8
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [21] The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
    Nyholm, Nanna
    Dansa, Anne
    Schnack, Henrik
    Colombo, Giorgio Lorenzo
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 607 - 619
  • [22] Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment or moderate-to-severe psoriasis in the UK
    Johansson, Erin Colleen
    Hartz, Susanne
    Kiri, Sandeep Himatlal
    Kumar, Gayathri
    Svedbom, Axel
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 810 - 820
  • [23] Biologic treatment sequences in moderate-to-severe psoriasis
    Ting, Samantha
    Lowe, Patricia
    Smith, Annika
    Fernandez-Penas, Pablo
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024,
  • [24] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [25] Cost-effectiveness of maintenance treatment for 1 year with biologic drugs for moderate to severe psoriasis in the dermatology department of a university hospital
    Lamas Domenech, Nuria
    Ramio, Elvira
    Serra Llobet, Jordi
    Sanchez Regana, Manuel
    Sola, Marian
    Iglesias Sancho, Maribel
    Salleras Redonnet, Montse
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB166 - AB166
  • [26] COST-EFFECTIVENESS OF USTEKINUMAB IN THE MANAGEMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MEXICO
    Valencia-Mendoza, A.
    Hernandez-Garduno, A.
    Puig, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A513 - A514
  • [27] Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective
    Igarashi, Atsuyuki
    Igarashi, Ataru
    Graham, Christopher N.
    Gilloteau, Isabelle
    Tani, Yumiko
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 7 - 15
  • [28] Cost-effectiveness of apremilast in moderate-to-severe chronic plaque psoriasis: a model analysis in the UK
    Mughal, F.
    Barker, J.
    Cawston, H.
    Damera, V.
    Bewley, A.
    Morris, J.
    Shaw, T.
    Tencer, T.
    Zhang, F.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 74 - 74
  • [29] Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
    Schweikert, Bernd
    Malmberg, Chiara
    Akerborg, Orjan
    Kumar, Gayathri
    Nott, Debby
    Kiri, Sandeep
    Sapin, Christophe
    Hartz, Susanne
    [J]. PHARMACOECONOMICS-OPEN, 2020, 4 (04) : 635 - 648
  • [30] Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
    Bernd Schweikert
    Chiara Malmberg
    Örjan Åkerborg
    Gayathri Kumar
    Debby Nott
    Sandeep Kiri
    Christophe Sapin
    Susanne Hartz
    [J]. PharmacoEconomics - Open, 2020, 4 : 635 - 648
12345